Biocogniv vs Warby Parker
Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA Breakthrough Device-designated AI platform predicting sepsis mortality risk in emergency departments; $17.08M from Breyer Capital and YC generating $2.6M revenue at 13-person Burlington-based team.
About
Biocogniv is a Burlington, Vermont-based clinical AI company that has developed an FDA Breakthrough Device Designation-granted platform for predicting sepsis-related mortality and ICU admission risk in emergency departments — using AI analysis of routine clinical data (vital signs, lab values, patient history) to identify patients at highest risk of deterioration hours before clinical signs become obvious to clinicians, enabling earlier intervention in one of healthcare's most time-sensitive conditions. Founded in 2019 and a Y Combinator W20 graduate, Biocogniv raised $17.08 million from Breyer Capital and YC, generating $2.6 million in revenue in 2024 with a 13-person team.
NYSE-listed (WRBY) DTC eyewear brand with $669M revenue and 240+ stores; vertical integration enabling $95-195 glasses competing with LensCrafters while pursuing profitability path after 2021 IPO.
About
Warby Parker is a New York-based direct-to-consumer eyewear company that disrupted the traditional optical retail industry by designing, manufacturing, and selling prescription glasses and sunglasses directly to consumers at $95-$195 price points — compared to $300-500 at traditional optical retailers that added brand markups, optician markups, and optical shop overhead. Listed on NYSE (NYSE: WRBY), Warby Parker generated $669 million in net revenue in fiscal year 2023 and operates 240+ retail stores across the US and Canada alongside its e-commerce and home try-on program.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.